MedTrace Logo

Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

NCT06264674 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 827

Last updated 2026-04-14

No results posted yet for this study

Summary

The CLI-05993AB6-03 Study is an interventional study designed to investigate the safety and efficacy of a new low global warming potential propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma

Conditions

Interventions

DRUG

CHF5993 200/6/12.5 μg pMDI HFA-152a

Pressurised Metered Dose Inhaler-2 inhalations twice daily

DRUG

Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Pressurised Metered Dose Inhaler-2 inhalations twice daily

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Dave Singh, MD · Medicines Evaluation Unit, Langley Building, Wythenshawe Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2025-02-18
Completion
2025-02-24

Countries

  • Bulgaria
  • Czechia
  • Georgia
  • Germany
  • Greece
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06264674 on ClinicalTrials.gov